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Polyornithine-based polyplexes to boost effective gene silencing 
in CNS disorders 
I. Conejos-Sáncheza,b (*),E. Gallona, A. Niño-Parientea, J. A. Smithb,d, A. G. De la Fuenteb,c, L. DiCaniob,c, 
S. Pluchinob, R.J.M. Franklinb,c, M.J. Vicenta (*)  
 
Gene silencing therapies have successfully suppressed the translation of target proteins, a strategy that holds great promise 
for the treatment of central nervous system (CNS) disorders. Advances in the current knowledge on multimolecular delivery 
vehicles are concentrated on overcoming the difficulties in delivery of small interfering (si)RNA to target tissues, which 
include anatomical accessibility, slow diffusion, safety concerns, and the requirement for specific cell uptake within the 
unique environment of the CNS. The present work addressed these challenges through the implementation of polyornithine 
derivatives in the construction of polyplexes used as non-viral siRNA delivery vectors.  Physicochemical and biological 
characterization revealed biodegradability and biocompatibility of our polyornithine-based system and the ability to silence 
gene expression in primary oligodendrocyte progenitor cells (OPCs) effectively. In summary, the well-defined properties and 
neurological compatibility of this polypeptide-based platform highlight its potential utility in the treatment of CNS disorders. 
Introduction 
Gene therapy based on small interfering RNA (siRNA) 
represents a clinically-applicable therapeutic stratey 
[1];however, setbacks concerning delivery have hampered 
development and highlighted important considerations for 
clinical translation. Enzymatic degradation, insufficient 
circulation lifetimes, reduced tissue penetration, cell 
endocytosis, and cytosolic transport often represent 
insurmountable biological barriers for unmodified siRNA. As a 
result, gene-silencing technology has only recently gained 
approval for clinical applications after almost two decades of 
intense research and development [2]. Patisiran® (ALN-TTR02 
[Alnylam]), the first therapy based on RNA interference (RNAi), 
is intended to treat transthyretin (TTR) amyloidosis by reducing 
the levels of a mutated protein whose fibrils accumulate and 
impact heart and nerve system function. The lipopeptide 
nanoparticles (NPs) transporting anti-mutant TTR siRNA [3] 
accumulate in the liver and kidney, the desired target for siRNA 
function. This successful therapeutic demonstration of a 
nanotechnological approach to siRNA delivery sparked renewed 
interest in RNAi-based therapies. Alnylam, also presents in its 
pipeline liver targeted siRNA-based gene therapy strategy: 
GalNAc-SiRNA conjugates [4]. The most advance example is 
Givosiran® for acute hepatic porphyria with excellent results in 
phase III clinical trials and has been very recently submitted for 
marketing authorization to the European Medicine Agency 
(EMA) [5].    
 siRNA therapeutics show promise for the treatment of a 
variety of otherwise untreatable pathologies, including central 
nervous system (CNS) conditions [6]thataffect more than one 
billion people worldwide, yet  suffer from a lack of therapeutics. 
siRNA can silence/ downregulate disease-related gene 
expression, including those traditionally considered to be 
undruggable, expanding putative therapeutic capabilities 
beyond traditional small-molecule drug-based approaches. 
siRNA also represents an ideal therapeutic candidate for chronic 
CNS disorders whose treatment requires long-term 
administration. Moreover, the high specificity of siRNA reduces 
unwanted side effects in the brain [6, 7]. Finally, RNA-based 
technologies are fast and relatively easy to develop, thanks to 
well-defined synthetic routes and bioinformatics tools that 
facilitate target identification.  
Of the >60 clinical trials involving siRNAs [8-10], less than 7% 
deal with CNS-related pathologies like glioblastoma, 
amyotrophic lateral sclerosis or multiple sclerosis (MS) [11]. 
Most research remains in early preclinical stages, as 
applications rely on effective blood-brain barrier (BBB) crossing 
while the therapeutic window for patient safety remains 
difficult to achieve. Among the nanotechnological platforms 
investigated for siRNA delivery, non-viral vectors represent a 
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favorable alternative to viral vectors. The clinical 
implementation of viral vectors has been restricted due to 
biosafety risks, uncertainties regarding the causes of adverse 
effects, low gene capacity, and inferior targeting [12]. Non-viral 
vectors are ostensibly less immunogenic and easier/cheaper to 
manufacture [13]. Polymer-based gene delivery systems are 
particularly enticing given an inherent structural/chemical 
versatility that facilitates control over physicochemical 
properties, vector stability, and larger gene capacity [14]. 
Furthermore, polymer-based systems display compatibility with 
good manufacturing practices and reproducibility in 
anticipation of translational manufacturing [15].  
Cationic polymers interact with siRNA via electrostatic 
interaction, resulting in polyplexes formation - multi-
component nanosystems belonging to the polymer 
therapeutics family [16]. To date, CALAA-01 represents the 
most successful example, comprising an siRNA targeting the M2 
subunit of ribonucleotide reductase complexed with a 
transferrin-coated self-assembling cationic cyclodextrin 
polymer conjugated with polyethylene glycol (PEG) that targets 
tumor cells overexpressing the transferrin receptor [8]. 
Polymers commonly investigated for CNS-related applications 
include polyethyleneimine, PEGylated-poly(amidoamine) 
(PAMAM) systems or PEGylated- polyaminoacids[17]. Although 
polyplexes have successfully delivered siRNA to the brain via 
intravenous or intranasal routes in preclinical studies, 
neurotoxicity-related issues and off-target effects related to 
poor biodistribution can hamper clinical translation, thus 
requiring the development of optimized siRNA delivery 
systems.  
 Biodegradable polymers, such as polypeptides, possess 
advantageous characteristics related to the safe and effective 
function of drug delivery vehicles. As an example, Opaxio, a 
poly(L-glutamic acid) conjugated to paclitaxel, has 
demonstrated safety and tolerability in clinical trials for high-
grade glioma and other cancer types [18, 19]. 
 We selected poly-L-ornithine (PLO) as a candidate for siRNA 
delivery to the brain. Ornithine (Orn) is a naturally-occurring 
non-proteinogenic amino acid containing a primary amine in 
the pendant group that provides the positive charge necessary 
for oligonucleotide complexation. To date, applications of PLO 
and Orn include: (i) gene silencing by polyplex formation 
(plasmid [20-22], DNA [24], and siRNA [25] complexation), (ii) 
cell penetration [26], (iii) growth improvement and cell [27-29], 
and (iv) coating materials [30], overall displaying lower 
immunogenicity than other cationic polypeptides. PLO also 
provides for tighter/stronger oligonucleotide condensation at a 
lower mass [23, 31] and increased resistance anionic counter 
species-mediated disruption [23].  
 To our knowledge, this study is the first to exploit PLO as a 
gene delivery carrier to the CNS. We describe a biodegradable 
PLO-based platform synthesized by N-carboxy anhydride (NCA) 
polymerization in a reproducible/scalable manner, resulting in 
a polypeptide with a controlled degree of polymerization and 
narrow molecular weight (MW) distribution. After post-
polymerization modifications, we created a library of PLOs that 
robustly form complexes with siRNA. Through an exhaustive 
physicochemical characterization, we also demonstrate the 
utility of this platform in terms of biocompatibility and 
biodegradability.   
 Aiming to mimic physiological conditions, we selected 
primary neural cells to evaluate gene silencing efficacy of novel 
polyplexes with a proposed application in the treatment of MS,. 
[32]. There is an immediate need for research into limiting MS 
progression, with a focus on delivering neuroprotective and 
neuroregenerative therapies. We explored our novel non-viral 
vectors as a means of promoting remyelination and axon 
regeneration by silencing death receptor 6 (DR6) viasiRNA 
delivery. Mi et al. [33] reported that DR6 negatively regulated 
oligodendrocyte (OD) survival, maturation, and myelination, 
and that attenuation of DR6 boosts remyelination and inhibits 
autoimmune activation in vivo. All OD subtypes express DR6 
during maturation, including oligodendrocyte progenitor cells 
(OPCs), and DR6 overexpression induced caspase-3 activation 
and cell death. 
Excitingly, our polyplexes provided sustained transfection 
efficiency in primary OPCs, a relevant in vitro model for 
potential neurotherapeutic applications. These results provide 
evidence for the promising future of PLO-based delivery in the 
development of siRNA-based therapies for CNS disorders. 
Results and Discussion 
1. Synthesis and characterization of poly-L-ornithine 
derivatives 
We selected PLO as a novel material with well-established 
potential in CNS applications to develop an efficient siRNA 
delivery system for the treatment of CNS disorders. Polyamino 
acids/polypeptides mimic natural proteins and possess 
demonstrated biocompatibility and biodegradability due to the 
endogenous nature of the monomeric building-blocks [43]. 
Often, biocompatible naturally-occurring biodegradable 
polymers (e.g. chitosan, cyclodextrins, etc.) present an inherent 
size heterogeneity (polydispersity index (PDI)>1.6) [44], which 
masks precise structure-activity relationships. Thus, to foster 
clinical translation it is required well-defined characterization 
and the minimization of variability through strict control of the 
production procedure. 
The first innovation in this study relates to PLO synthesis; we 
synthesized PLO using a facile and versatile methodology based 
on ROP-NCA chemistry (ring-opening polymerization of α-
amino acid N-carboxyanhydrides) that permits the reproducible 
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generation of well-defined homogenous polypeptides [45]. This 
potent methodology allows for the synthesis of well-defined 
polypeptides on multigram scales and with low polydispersity 
(PDI <1.2), adjustable MW, controlled chain end-functionality, 
and robust  stereoselectivity, all ideal features for biomedical 
applications and industrial development [46]. Currently 
published studies exploit PLOs with broad MW distributions 
and/or structural heterogeneity, which might impede drug 
development and regulatory approval. In our study, we 
synthesized PLO using ROP-NCA, giving a high-quality polymer 
with low polydispersity. As remarked before, these 
characteristics are crucial for further translational 
manufacturing. 
PLO (P) derivatization resulted in the generation of four 
different products: P1 (PLO-2PD), P2 (PLO-PEG3000), P3 (PLO-
PEG3000Fmoc), and P4 (PLO-PEG2000) (Figures 1A and S2). The 
major concern driving the derivatization of PLO was to at least 
partly neutralize the cationic character of the main chain to 
decrease any associated cellular toxicity, minimize electrostatic 
interactions, reduce protein binding, and modulate nucleic acid 
complexation capabilities. Therefore, we introduced different 
moieties into the main chain by covalent linkage via the pendant 
amino groups. Interestingly, studies have demonstrated that 
aromatic molecules such as peptidic residues (e.g., tyrosine, 
phenylalanine, or tryptophan) or drugs (e.g., doxorubicin or 
daunomycin) can complex DNA/oligonucleotides [47-51]. 
Aromatic residues may intercalate into the nucleic acid base 
pairs, contributing to improved condensation and providing 
higher transfection efficiency. Therefore, we decided to study 
the stabilizing effect of introducing aromatic molecules into the 
polymer, e.g., pyridyl moieties (P1) and the Fmoc group (P3) 
(Figure 1A); the hydrophobicity of the Fmoc moiety in P3 may 
induce conformational changes in comparison with the P2 
derivative. The pyridyl moiety can promote crosslinking with 
free amino groups via the reactive thiol group [52], which might 
contribute in creating clusters to better accommodate siRNA 
complexation.  We also covalently attached PEG chains onto the 
polymer backbone pendant groups to increase polyplex steric 
stability and prevent non-specific interactions [53]. In the 
context of CNS disorders, PEGylation contributes to generating 
a near-neutral surface charge that favors the spread of the 
polymer throughout the brain [54-56]. Therefore, we examined 
two different PEGs (MW of 2,000 g/mol (P2) and 3,000 g/mol 
(P4)). Polymer derivatization can modify the polymer’s in vivo 
fate, biodistribution, and thus, therapeutic activity. 
We calculated the substitution degree of all derivatives 
(Figure 1B) from the corresponding peak intensity ratio 
between the PEG or 2PD (pyridyl disulfide) protons and the PLO 
protons in the 1H-NMR spectra (Figure S3A-D). We observed 
different retention times upon analysis of the derivatives by gel 
permeation chromatography (GPC), indicating that differences 
in MW depend on the introduced motif (Figure 1C and S4). As 
part of the characterization of these novel derivatives, 
diffusion-ordered NMR spectroscopy (DOSY NMR) studies 
determined diffusion coefficients (Figure 1B) and proved the 
successful conjugation of the residues (2PD, PEG or PEG-Fmoc), 
verifying identity and purity. This diffusion coefficient is 
inherent to the product and relates not only to intrinsic 
properties (size, shape, MW, charge, etc.) but also to the 
surrounding environment (e.g., concentration, solvent, 
temperature, etc.). This technique has been applied in different 
contexts, including MW prediction, predicting the effect of 
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shape in polymers, bioconjugation studies, and polypeptide 
studies [57-61].  
NMR results indicated that, after derivatization, PEG-
derivatives displayed a slight increase in size, which further 
diminishes their diffusion coefficient. This data highlights the 
influence of the conjugated moieties on the size in solution, 
which can treble the initial hydrodynamic radius (Rh). In the 
case of 2PD derivation (P1), the diffusion coefficient (D) 
increases; the low MW of the 2PD molecule in comparison with 
the polymer and the possible conformation of the derivative 
result in a smaller size in solution than the polymer alone. We 




PLO P - 4,43E-11
PLO- 2PD P1 8 4,96E-11
PLO - PEG3000 P2 1,4 4,08E-11
PLO - PEG3000-Fmoc P3 2,7 4,11E-11
PLO - PEG2000 P4 1,8 4,12E-11
*1H-NMR 
(D2O)
 # DOSY 
(D2O)















Figure 1. (A) Poly-L-ornithine derivatives (P1-P4). (B) Molar percentage of 
modification calculated by 1H-NMR and diffusion coefficients of the obtained 
derivatives by DOSY. (C) Degradation of  P2  monitored by GPC (PLO150). 
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interacting through π-π interactions due to the aromaticity of 
the molecule can result in a more compact structure than PLO. 
The use of polymeric systems based on amino acids as drug 
delivery carriers provides the advantage of fully biodegradable 
vehicles. Although ornithine is a non-essential amino acid, it is 
generated in the body through several mechanisms and 
degraded into non-toxic metabolites [62]. PLO degradation 
inside the human body has yet to be extensively studied [63], 
and polymer chemical modification might impact the 
degradation rate of the final construct. Therefore, we studied 
the biodegradability of the newly synthesized polymers under 
various enzymatic conditions. The protease cocktail mixture 
employed contained a non-specific enzymatic matrix composed 
of at least ten proteases [64]. Previous studies have 
demonstrated that trypsin, chymotrypsin, or papain fail to 
degrade PLO [65-67], although metallocarboxypeptidases can 
catalyze the hydrolysis of basic amino acids such as ornithine 
[68]. We observed the degradation of modified PLO by a 
protease cocktail (Figures 1C and S4) with no effect of PEG 
derivatization on the degradation of the polymer, supporting 
the adequacy of the derivative for in vivo purposes. 
2. Preparation and Characterization of siRNA Polyplexes  
We prepared PLO polyplexes (Px, Px1, Px2, Px3, Px4) by 
mixing siRNA (or dsDNA, where indicated) and the 
corresponding polymer at varying molar ratios of amines in PLO 
to phosphates in siRNA (define as N/P ratio). We assessed 
oligonucleotide complexation by gel shift assay to evaluate the 
best N/P ratio (Figure S5). Increased electrophoretic migration 
retardation was observed at higher N/P ratios, yet all ratios 
tested (N/P from 2 to 10) demonstrated successful 
complexation. We next assessed the in vitro biocompatibility of 
these novel polymers by colorimetric (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) (MTS) viability assays in the B16-F10 melanoma 
cell line as a preliminary screening cell model for our PLO 
derivatives (Figure S6). N/P ratios 3 and 4 did not compromise 
cell viability, and we selected N/P ratio 3 for further 
experiments to use the least amount of polymer. 
Dynamic light scattering (DLS) revealed that all polyplexes 
displayed similar physicochemical properties, including a 
hydrodynamic diameter of 30-60 nm and PDI below 0.2, 
associated with a unimodal size distribution (Figures 2A and S7). 
Size comparison with hydrodynamic radius (Rh) of parent 
polyplexes (Table S1) can indicate that compaction occurred 
due to siRNA complexation. We discovered the zeta-potential 
for the derivatized polyplexes to be roughly half the value of a 
PLO polyplex (30±2 mV) (Figure 2A), confirming the expected 
decrease in charges after chemical modification. We observed 
a slightly neutral-to-positive final zeta-potential for the 
polyplexes (Px1-Px4). siRNA delivery generally required 
positively-charged carriers for electrostatic interactions with a 
negatively-charged oligonucleotide cargo. The cationic systems 
reported in the literature (e.g., PEI, PAMAM, etc.) are often 
affected by aggregation, toxicity, premature sequestration by 
phagocytic cells, and non-specific cell membrane and serum 
protein-interactions [69]. Thus, modulation of positive charges 
represents a critical issue that must be addressed during 
delivery vehicle optimization. Some comparable cationic 
polypeptidic graft copolymers have demonstrated their 
potential as biocompatible carriers for other biomedical 
applications [70]. 
Transmission electron microscopy (TEM) images confirmed 
the DLS-measured sizes of the polyplexes, which displayed a 
biconcave disc morphology (Figures 2B and S8). Due to the 
concentration-dependent limitations of the technique, we 
carried out a parallel DLS study to confirm that concentration 
did not affect the apparent polyplex size (Figure S9). In addition, 
we observed the same morphology for all derivatives at all 
tested concentrations. 
Circular dichroism (CD) spectroscopy is a powerful tool for 
the study of dynamic alteration to secondary structures and the 
conformations adopted by biomolecules such as nucleic acids, 
proteins, or synthetic polypeptides under various conditions 
[71-73]. In this study, we employed far-UV analysis (180-250 
nm, where peptidic bonds reveal secondary structure 
characteristics) to estimate the influence of PLO main chain 
modification. Also, the application of this technique to certify 
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the complexation process can confirm the interaction of the 
dsDNA/siRNA with the polymeric derivative. We selected 
phosphate buffer (PB) as a solvent to analyze all components. 
First, we confirmed the similarity of the dsDNA band pattern to 
that previously reported [74, 75].  As expected, the unmodified 
PLO spectrum resembled that of a random coil structure (Figure 
S10A). All derivatives (P1-P4) demonstrated slight changes 
compared to unmodified PLO but still maintained the 
appearance of a random coil structure after chemical 
modification. Only P3 exhibited a marked increase in molar 
ellipticity at 195 nm and a small decrease at ~220 nm that can 
likely be attributed to interactions among the Fmoc groups. 
Analysis of polyplexes suggested the retention of the ellipticity 
characteristic of their polymeric counterpart (Figure S10B). In 
the case of PEG derivatives (P2, P3, and P4), the differences 
observed in comparison with each correspondent derivative 
(e.g., shifts in the area 190-200 nm and at approx. 250 nm) 
might be ascribed to complexation with the dsDNA, confirming 
the co-existence of both species in the polyplex. The 
conformation of PLO is downgraded when dsDNA is complexed, 
with the observation that Px2 and Px3 presented a higher 
prevalence of dsDNA structure and higher trend to adopt an 
alpha-helix conformation.  
Next, we performed stability studies, mimicking in vitro or 
in vivo scenarios, to assess the ability of the polyplexes to 
release siRNA. We employed the polyanion heparin as an 
indicator of binding strength between siRNAs and cationic 
polymers [76, 77] as heparin acts as a competing polyanion, 
triggering polyplex disassembly. Our  polyplexes (Px: 0.011, Px1: 
0.015, Px2: 0.016, Px3: 0.022, Px4: 0.018 mg/mL) demonstrated 
stability in the presence of up to 0.75 IU of heparin per 20 μL 
(this corresponds to 75 IU/100 mL, well above the average 
heparin levels in human plasma, which only reach 15 IU/100 mL 
[78]) (Figure 2C). We applied an excess of heparin to prove 
siRNA/dsDNA release (1 IU per 20uL, 5000 IU/100mL), verifying 
the integrity of the polyplex under the selected conditions. 
Before in vitro experiments, we studied polyplex stability in 
B16-F10 and OPC cell media. Serum is often present in cell 
media and contains abundant polyanions, such as 
proteoglycans and glycosaminoglycans, that can promote 
oligonucleotide release from the complex. Encouragingly, we 
discovered complex stability after 24 hours of incubation in cell 
medium (with and without serum), thereby indicating the 
overall stability of polyornithine complexes (Figure S11).  
Envisioning the possible intravenous (i.v.) administration of 
these novel polyplexes, we next determined blood stability of 
polyplexes and their ability to induce red blood cell (RBC) lysis 
as a means to predicting their integrity and safety for in vivo 
administration [79]. The RBC hemolysis assay can also help to 
determine pH-dependent membrane disruption. Stability at pH 
7.4 mimics the conditions faced by the polyplex following i.v. 
administration, as well as the pH in extracellular and cytosolic 
environments. All polyplexes and their parent polymers 
displayed <5% hemolysis at pH 7.4 when employing a polymer 
concentration range of 0.05-0.005 mg/mL (polymer content), 
thereby suggesting suitability for i.v. administration in this 
concentration range (Figure S12). At 0.1 mg/mL, all polyplexes 
displayed hemolytic behavior at low pHs, suggesting possible 
efficient endosomal disruption/escape. For subsequent activity 
experiments, we employed a concentration of 0.05 mg/mL in 
the hope of maximizing dosage without reaching hemolytic 
levels. We further evaluated the stability of the siRNA 
polyplexes in blood (Figure 2D and S13). The complexes 
remained stable for at least 5 h in plasma, confirming their 
suitability for systemic delivery applications. Finally, we 
analyzed the stability of preformed polyplexes (in suspension) 
at 4°C for 15 days (Figure S14) to mimic relevant conditions for 
short-term storage. Of the four polyplexes, only Px2 displayed 
non-significant variations in both size and Z-potential (Px1 
displayed a substantial increase in size over time, while both Px3 
and Px4 underwent considerable Z-potential increases). 
3. In vitro Validation of PLO Polyplexes 
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Once we demonstrated the ability of these novel polymeric 
nanocarriers to form stable and biodegradable siRNA 
complexes effectively, we next aimed to verify their 
biocompatibility and functionality as gene silencing vectors. 
Luciferase Inhibition 
Initially, we employed luciferase (luc) transfected cells (B16-
F10-luc-G5) as a cell model to quantify gene silencing, with luc 
as the reporter protein. Cell proliferation (MTS) assays carried 
out in B16-F10 cells revealed high cell viability after treatment 
with all polyplexes (≥85% for Px1, Px2 and Px3, and ≥75% for 
Px4) (Figure S15), independent of the siRNA payload (non-
targeted control (NT) or Luc), or the parent polymers (Figure 
S6). All the systems exhibited similar equivalent silencing of 
luciferase gene expression (~50-68% reduction), thereby 
proving the capacity of PLO derivatives to deliver siRNA (Figure 
S16) efficiently. Given these encouraging results, we next tested 
these polyplexes in an in vitro model relevant to 
neurodegenerative disorders. 
Figure 2. (A) Study of size (black bars) and Z-potential (red squares) of the polyplexes by DLS [pol] = 0.012 mg/mL and (B) 
representative TEM images of the polyplex Px2 [pol] = 0.12 mg/mL (diameter = 44.7 ± 10.5 nm). (C) Stability studies by shift-gel assay 
of the polyplexes after their dilution in OPC cell media and after 1h incubation at 37°C. 1 IU/mL of heparin was added after the 1 h at 
37 °C incubation to disassemble the polyplex and verify the presence of the siRNA in the complex.  NT = non-target siRNA. (D) Plasma 

















































 d (nm) PDI 
Z-potencial 
(mV) 
Px 48 ± 3 0.206 30 ± 2 
Px1 60 ± 11 0.138 16 ± 2 
Px2 40 ± 5 0.140 10 ± 1 
Px3 51 ± 11 0.146 13 ± 1 
Px4 36 ± 9 0.150 8 ± 2 
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DR6 Inhibition 
The Death receptor 6 (DR6) protein is involved in several 
neurodegenerative disorders. As a member of the tumor 
necrosis factor (TNF) receptor family (a.k.a. TNF receptor 
superfamily member 21 (TNFRSF21)), DR6 regulates apoptosis 
through caspases in a range of neural cell types [80, 81]. 
Upregulation of DR6 has been reported to result in (i) caspase 3 
(Casp3) activation, axon degeneration, and motor neuron death 
in ALS [82], (ii) Casp6 and Casp3 activation and induction of 
axonal degeneration in prion-related diseases [83], and (iii) 
Casp3 activation, oligodendrocyte cell death, and 
demyelination [33]. In this latter example, Mi et al. described 
how DR6 attenuation enhanced oligodendrocyte maturation 
and myelination and inhibited autoimmune activation during in 
vivo studies in an animal model of MS. Recent studies also 
suggested that DR6 plays a role in T helper cell activation, with 
a potential role in inflammation and immune regulation [84, 
85]. 
In this study, we focused on silencing DR6 in primary OPCs to 
validate our polyplexes as gene silencing vectors as a potential 
treatment for MS. Primary cells constitute a step up in 
complexity over immortalized cells in in vitro models, ostensibly 
providing a more realistic scenario, a critical point in the 
Figure 3. Safety and gene silencing in primary OPCs. (A) LDH cytotoxicity assay 48 h post-transfection. n > 3, mean ± SEM. 
Indicated concentrations corresponds to siRNA. (B) qPCR assays showing the knockdown of Tnfrs21 target mRNA by 
polyplexes.  Downregulation measured 48 h after transfection. Lipofectamine or NT siRNA polyplexes were used as 
negative controls. GAPDH was selected as the reference gene. (B) Study of PLO derivates at 100nM (siRNA concentration) 
and (C) concentration study of Px2. Data from the experiments were analyzed using one-way ANOVA and Bonferroni 
posthoc for pairwise comparison. In all cases, differences were considered to be significant when ***p < 0.001; **p < 
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development of regenerative therapies in the CNS. We 
prepared OPCs from newborn rat brains as previously described 
[86], which involves A2B5 magnetic cell sorting to obtain pure 
OPC cultures (90% A2B5+ cells) from the neonatal brain while 
avoiding the culture of cells in mixed glial cultures. This setup 
allows us to study the role DR6 silencing directly in OPCs, 
avoiding off-target effects that could happen in mixed glial 
cultures, as well as eliminating the presence of FBS in the media 
which is always a confounding factor. 
Having established N/P 3 as the effective ratio for gene 
silencing, we tested several siRNA concentrations at this ratio in 
OPCs (from 25 to 200 nM). Transfection of OPCs with the 
polyplexes proved to be non-toxic for 48 h post-transfection at 
concentrations up to at least 100 nM, as verified by colorimetric 
LDH cytotoxicity assay (Figure 3A).  
We then proceeded to study DR6 downregulation at mRNA 
and protein level. Transfection with Px1, Px2, and Px3 at 100 nm 
[siRNA] led to a decrease in Tnfrsf21 expression relative to non-
transfected cells (35%, 36% and 39%, respectively), as observed 
in the analysis of mRNA levels via qPCR (Figure 3B). Delivery of 
NT negative control siRNA resulted in no significant change in 
the expression of Tnfrsf21. In comparison, siRNA-mediated 
knockdown using Lipofectamine (LF) as a transfection reagent 
yielded a lower silencing effect (18%). Higher concentrations of 
LF as a transfection agent further enhanced gene silencing due 
to higher cytotoxicity in OPCs. A more exhaustive assay with Px2 
revealed a dose-dependent silencing response, in which 200 nM 
decreased Tfnrsf21 by >60% (Figure 3C). We do note that the 
only two of the four siRNAs that compose the siRNA pool 
targeted rat sequences; therefore, further optimizing the siRNA 
pool to more fully target the rat sequences may further 
potentiate the silencing effect. 
At this stage, we selected P2 as the candidate with which to 
move forward with protein knockdown studies owing to its 
better stability, lower apparent cytotoxicity, and greater 
downregulation efficacy in qPCR studies. We chose a siRNA 
concentration of 100 nM and performed protein collection four 
days post-transfection, as downregulation of DR6 was not 
observed until 48 h after gene silencing (Figure S17). Px2/DR6 
induced a significant reduction in DR6 protein expression 
(Figure 4A); DR6 levels decreased 34% upon Px2/DR6 treatment 
relative to the non-treated control. Interestingly, Lipofectamine 
(LF/DR6) failed to silence DR6 at the protein level at 48 h or 4 
days after transfection (Figure S17), suggesting the potent 
nature of our newly developed polyplexes. We examined 
poly(ADP-ribose) polymerase (PARP) expression to assess the 
effect of DR6 silencing on Casp3 activation. PARP is a Casp3 
substrate whose cleavage constitutes a hallmark of apoptotic 
cells [85, 86]. A 49% reduction in PARP upon Px2/DR6 treatment 
(Figure 4A) verified the correlation between DR6 and Casp3 
established in the literature. However, when we analyzed the 
expression levels of proteins known to be markers of OPC 
differentiation and maturation after DR6 knockdown, including 
2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP), myelin-
associated glycoprotein and myelin oligodendrocyte 
glycoprotein, we did not observe any differences between 
treated and control samples (Px and LF) (Figure 4B). To validate 
this result, we performed further qualitative assessments of 
OPC maturation markers by immunofluorescence assays. To 
determine OPC maturation after DR6 silencing, we addressed 
the various differentiation/maturation stages using three 
different markers: Olig2 a pan-oligodendrocyte marker staining 
OPCs and mature oligodendrocytes; O4, a marker for immature 
and mature oligodendrocytes; and CNP, a marker for mature 
oligodendrocytes [89]. We analyzed the proportion of Olig2+ 
cells expressing the immature marker O4 and the mature 
marker CNPase and observed no differences between those 
treated with control NT siRNA polyplexes or DR6 siRNA 
polyplexes. Despite DR6 knockdown at the gene and protein 
level, this downregulation seemed to have no effect on the 
ability of OPCs to differentiate into mature oligodendrocytes, 
nor their morphology (Figure S18). Therefore, protein analysis 
by Western blot and immunocytochemical analysis of OPC 
differentiation revealed that independent to the efficacy of the 
polyplexes to silence DR6 in OPCs, DR6 silencing did not 
translate into enhanced OPC maturation as published 
previously [33]. 
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In parallel with these studies, we evaluated cell viability and 
gene silencing efficiency in other neural cell types. For example, 
we observed that our Pxs were non-cytotoxic in neural stem 
cells (NSCs), NSC-derived astrocytes, and two immortalized OPC 
cell lines: CG-4 [90, 91] and BO-1 [92] (Figure S19A-C). 
Additionally, did not succeed in downregulating DR6 in any of 
these cell lines (NSCs, BO-1, and CG-4), supporting the relevance 
of primary cell culture as a more realistic in vitro model for our 
aims, and the marked biocompatibility of our polyplexes with 
different brain cells. 
Conclusions 
Recent developments in nanotechnology have established 
extraordinary opportunities to address the biological challenge of 
making siRNA a feasible therapeutic approach for the treatment of 
CNS disorders. Previously reported non-viral systems have 
succeeded in effective brain delivery via i.v. or intranasal routes in 
preclinical studies; however, clinical translation of such platforms can 
be hampered by neurotoxicity-related problems and/or off-target 
effects due to inadequate biodistribution. To address these critical 
problems, we described, for the first time, novel biodegradable PLO-
based polyplexes for the delivery of siRNA to neural cells. This amino 
acid-based synthetic polymer exhibits several advantages over 


























Figure 4.  Densitometry-based quantification of (A) DR6 (68 KDa), cleaved PARP (89 KDa), and (B) CNP (48 KDa) Western 
blots showing siRNA-induced protein knockdown and a representative image. Quantification is expressed relative to β-
actin and normalized to non-transfected control samples. 
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homogenous polypeptide through a robust and scalable 
polymerization procedure. 
Moreover, we accomplished PEG-derivatization employing a 
well-established and straightforward methodology that did not alter 
the secondary structure of the main polypeptidic chain, as 
demonstrated by CD. Secondly, we established platform 
biodegradability, addressing the critical concern of drug carrier 
degradation after siRNA delivery. These characteristics are amenable 
to the future industrial scale-up of manufacturing as well as clinical 
translation.  
The modification of the well-defined PLO chain with different 
PEG motifs or the small molecule 2PD gave rise to systems that 
formed complexes with siRNA. These nanocarriers facilitated 
oligonucleotide delivery by improving their stability in vitro and 
under in vivo-mimicking conditions. With neurological disorders 
commonly affecting specific parts of the CNS, and even sub-
phenotypes of neural cells, the route of administration is a crucial 
aspect of nucleic acid delivery [69]. Envisioning the i.v. 
administration of our PLO-derivatives, we demonstrated stability in 
the bloodstream, with complexes remaining intact for at least 5 h. 
Also, they were found to be non-haemolytic. For i.v. delivery, the 
final design will include a blood-brain barrier-targeting moiety (e.g., 
the Angiopep2 peptide) to favor uptake [17]. Another possibility will 
be the formulation of our polyplexes for intranasal administration, 
providing a direct delivery via nose-to-brain pathway [17]. 
Furthermore, increased selectivity towards the final target cell 
through the incorporation of another cell-specific targeting moiety 
will be required to realize the full potential of this proposed siRNA-
based therapy. Fortunately, the multifunctional nature of PLO 
facilitates the conjugation of multiple moieties within the same 
polymer main chain. For intranasal administration, the inclusion of 
our PLO-derivative in a polymeric hydrogel, creating a multicomplex 
system, will endow the carrier with increased nose-to-brain delivery 
[14].  
As a preliminary proof of activity, we successfully employed PLO 
complexes in the transfection of B16-F10 cells, as demonstrated by 
luciferase assay. Further evaluation of therapeutically active 
polyplexes in primary OPCs underpinned their efficacy in silencing 
DR6, as established by qPCR assays. Px2 (PLO-PEG3000) 
demonstrated the highest silencing efficiency, suggesting the 
relevance of the MW of the introduced PEG. We observed a 
concomitant reduction in DR6 and PARP protein expression, thus 
corroborating the reported connection between DR6 and cell death 
through the Casp3 pathway. However, we found no evidence of 
effects on OPC differentiation and maturation after DR6 silencing. 
Regardless of this fact, our polyplexes have shown their ability to 
facilitate gene silencing in primary neural cells, in parallel with their 
biocompatibility with other neural cell types. Within this context we 
would like to draw attention to the vital importance of the selection 
of the in vitro model, because our nanocarriers worked efficiently 
with primary cells. In addition, our polyplexes were found to be safe 
in a diversity of brain cells.   
In summary, we have described the implementation of novel 
biodegradable and biocompatible polyornithine derivatives as non-
viral vectors for siRNA that effectively silence gene expression in 
primary neural cells. We postulate that this well-defined polypeptidic 
platform and its suitability for applications in neural cells will 
translate into effective therapies for the treatment of CNS disorders. 
Experimental 
Materials 
Poly-L-ornithine (PLO, 5,700 g/mol, n=50, PDI = 1.09) was 
provided by Polypeptide Therapeutic Solutions SL. (PTS; 
Valencia, Spain). 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl 
morpholinium chloride (DMTMM·Cl) salt was synthesized, 
according to Kunishima et al.  [34] and the tetrafluoroborate salt 
(DMTMM·BF4) according to Kamiński et al. [36]. Pyridyl dithiol 
ethylamine HCl salt was synthesized as described in van der 
Vlies et al. [36]. All other chemicals were reagent grade and 
used without further purification. The mono or 
heterobifunctional poly(ethylene glycol) (PEG) derivatives 
mPEG(3000)-NHS (3,023 g/mol), Fmoc-PEG(3000)-NHS (3,219 
g/mol) and mPEG(2000)-COOH (2,015 g/mol), where NHS is N-
hydroxysuccinimide, and Fmoc is the 
fluorenylmethyloxycarbonyl protecting group, were supplied by 
Iris Biotech (Germany). 
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N,N-dimethyl aminopyridine (DMAP), diisopropylethylamine 
(DIEA), ethylenediaminetetraacetic acid (EDTA), anhydrous 
dimethylsulfoxide (DMSO), poly-D-lysine (PDL, 70,000-
150,000g/mol), phenylmethanesulfonyl fluoride (PMSF), 
tris(hydroxymethyl)aminomethane (TRIS), and Streptomyces 
griseus protease cocktail were obtained from Sigma Aldrich. PD-
10 Columns Sephadex G-25 M for size exclusion 
chromatography (SEC) and ECL Prime Western Blotting System 
(RPN2232) were obtained from GE Healthcare. Deuterated 
solvents, such as deuterated oxide (D2O), were purchased from 
VWR (Spain). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) was purchased from Biomol GmbH, while agarose 
(Molecular Biology Grade) was obtained from Fisher Scientific. 
All siRNAs (siGENOME Mouse Tnfrsf21 (94185) siRNA – 
SMARTpool, Luciferase GL3 Duplex (siRNA) and ON-TARGETplus 
Non-targeting Pool siRNA) were purchased from Dharmacon 
(Cultek, Spain). The QIAzol Lysis Reagent was purchased from 
QIAGEN, and the Complete Protease Inhibitor Cocktail was 
purchased from Roche. All RNA solutions and buffers were 
prepared using RNAase-free water. 
Dulbecco’s Modified Eagle’s Medium (DMEM), phosphate-
buffered saline (PBS), fetal bovine serum (FBS), penicillin, 
streptomycin, and trypsin were provided from Gibco Life 
technologies. The MTS and Bright-Glo Luciferase Assay systems 
were supplied by Promega. The LDH-Cytotoxicity Assay Kit II and 
radioimmunoprecipitation assay (RIPA) buffer (10X) were 
purchased from Abcam. High-Capacity cDNA Reverse 
Transcription kit was obtained from Life Technologies.  
OPC isolation was performed using papain (Worthington), 
Hybernate A (produced in-house), DNase (Sigma-Aldrich), B27 
(Gibco Life Technologies), 10% pluronic acid (Gibco Life 
Technologies), Percoll (GE Healthcare), 10X PBS ( Gibco Life 
Technologies), 7.5% Bovine Serum Albumin fraction V (Gibco 
Life technologies), 0.5M EDTA pH=8.0 (Gibco Life technologies), 
recombinant insulin (Gibco life technologies), anti-Mouse A2B5 
antibody (Millipore, MAB312), Anti IgM Microbeads (Miltenyi 
Biotech), and Magnetic Cell Separation kit from Miltenyi 
Biotech.  
OPC media was composed of DMEM F12 (Gibco life 
technologies), 1.5 mM sodium pyruvate, 25 mM D-glucose 
(Sigma Aldrich), 10 µg/mL insulin (Gibco life technologies), 60 
µg/mL N-acetyl cysteine (Sigma-Aldrich), 50 µg/mL apo-
transferrin (Sigma-Aldrich), 16.1 µg/mL putrescine (Sigma-
Aldrich), 40 ng/mL sodium selenite (Sigma-Aldrich), and 60 
ng/mL progesterone (Sigma-Aldrich). Growth factorsBasic 
fibroblast growth factor (bFGF) (10 ng/mL) and platelet-derived 
growth factor AA (PDGF-AA) (20 ng/mL) (Peprotech) were 
supplemented daily. 
Cells were plated on 5 µg/mL PDL-coated plates at a density of 
either 143 cells/mm2 or 31 cells/mm2 depending on the 
experiment set-up.  
Polyvinylidene difluoride (PVDF) transfer 0.45 μm membranes 
for Western blotting, Lipofectamine RNAiMAX Transfection 
Reagent, TaqMan Fast Universal PCR Master Mix (2✕) No 
AmpErase UNG, DR6 Taqman probe (Mm00446361_m1 
Tnfrsf2), Mouse GAPDH endogenous control Taqman probe 
(4352339E), Halt Phosphatase Inhibitor Cocktail, and Pierce BCA 
Protein Assay kit were obtained from Thermo Fisher. The 
intercalating agent GelRed was purchased from Biotium/VWR. 
Immunofluorescence reagents: normal donkey serum (NDS) 
was acquired from Sigma-Aldrich. Primary antibodies: rabbit 
anti-Olig2 (AB9610) was obtained from Millipore; mouse anti-
CNPase (C5922) and Hoechst from Sigma-Aldrich and O4 from 
R&D systems. Fluoromount G was obtained from Southern 
Biotech (Birmingham, AL) Primary antibodies western blot: 
Cleaved Caspase-3 (Asp175) #9661 and poly(ADP-ribose) 
polymerase (PARP) #9542 antibodies were acquired from Cell 
Signaling Technology. DR6/TNFRSF21 Antibody (NBP1-45952) 
was purchased from Novus Biologicals. A β-actin antibody was 
obtained from Merck Millipore. Secondary antibodies: Goat 
Anti-Rabbit IgG H&L (HRP) (ab205718) was acquired from 
Abcam, mouse anti-rabbit IgG-HRP (sc2357) was obtained from 
Santa Cruz Biotechnology, Inc and anti-mouse IgG (A9044) from 
Sigma Aldrich. 
Methods 
1. Synthesis and Characterization of poly-L-ornithine Derivatives  
1.1 Synthesis of PLO50 Derivatives 
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PLO-2PD (P1). One eq. of PLO50 Br salt (0.15 mmol, MW 195 
per unit) was dissolved in 1 mL of PBS-EDTA 10mM under 
agitation at room temperature (RT). Then, 0.1 eq. of pyridyl 
dithiol cysteamine (2PD) previously dissolved in 200 µL of DMSO 
was added dropwise to the PLO solution. The reaction was 
allowed to proceed for 1 h under agitation at RT. Then, the 
reaction volume was lyophilized, and the residue resuspended 
in double-distilled water (ddH2O) and purified on a PD-10 
column. Fractions were lyophilized and the obtained solid 
analyzed by 1H NMR and DOSY (D2O). 1H NMR δH (300 MHz, 
D2O): 8.41-7.31 (4xH, m), 4.34 (1H, m), 3.21-3.06 (4xH + 2H, m), 
1.82 (4H, m). x: percentage of modification. 
PLO-PEG3000 (P2). All reagents were weighed in separate 
recipients and purged under N2 flow before and during their 
solution. In a two-necked round bottom flask, fitted with a stir 
bar and two septae, 1 eq. of PLO50 Br salt (0.15 mmol, MW 195 
per unit) was dissolved in 2 mL anhydrous DMSO under 
magnetic stirring. Then, mPEG(3000)-NHS (0.01 eq.) dissolved 
in 1 mL DMSO was added to the flask followed by a catalytic 
amount of DMAP (previously dissolved in 200 μL DMSO). pH was 
adjusted to 8 with DIEA, and the reaction was left under 
magnetic stirring for 36 h. The solvent was removed under 
reduced pressure, and the product was re-suspended in 300 μL 
of Milli-Q water and purified by size exclusion chromatography 
(G25, PD-10 column). Fractions were lyophilized and the 
obtained solids analyzed by 1H NMR and DOSY (D2O). 
1H NMR δH (300 MHz, D2O): 4.41 (1H, m), 3.74 (68xH + 4H m), 
3.07 (2H, m), 1.82 (4H, m). x: percentage of modification. 
PLO-PEG3000Fmoc (P3). All reagents were weighed in separate 
recipients and purged under N2 flow before and during their 
solution. 1 eq. of PLO50 Br salt (0.15 mmol, MW 195 per unit) 
was dissolved in 2 mL DMSO anhydrous under magnetic stirring. 
Fmoc-PEG(3000)-NHS (0.01 eq.) previously dissolved in 1 mL 
DMSO was added to the flask followed by a catalytic amount of 
DMAP (previously dissolved in 200 μL DMSO). pH was adjusted 
to 8 with DIEA and reaction was left under magnetic stirring for 
72 h. The solvent was removed under reduced pressure, and the 
product was re-suspended in 300 μL of Milli-Q water and 
purified by size exclusion chromatography (G25, PD-10 column). 
Fractions were lyophilized and the obtained solids analyzed by 
1H NMR and DOSY (D2O). 
1H NMR δH (300 MHz, D2O): 4.41 (1H, m), 3.74 (68xH + 4H m), 
3.07 (2H, m), 1.82 (4H, m). x: percentage of modification. 
PLO-PEG2000 (P4). All reagents were weighed in separate 
recipients and purged under N2 flow before and during their 
solution. P4 was synthesized using DMTMM with a modification 
of a previously published method [37]. In a two-necked round 
bottom flask fitted with a stir bar and two septae, mPEG(2000)-
COOH (0.01 eq, 0.0021 mmol) dissolved in 1 mL anhydrous 
DMSO. To the resulting suspension, DMTMM·BF4 (0.02 eq., 
0.004 mmol) dissolved in 0.3 mL of anhydrous DMSO was added 
dropwise and stirred at RT for 15 min. Subsequently, PLO50 
(MW 195 per unit, 0.2 mmol, 1 eq.) dissolved in 1 mL anhydrous 
DMSO was added, and the reaction mixture was stirred for 72 
h. The solvent was removed under reduced pressure, and the 
product re-suspended in 300 μL of Milli-Q water and purified by 
size exclusion chromatography (G25, PD-10 column). Fractions 
were lyophilized and the obtained solids analyzed by 1H NMR 
and DOSY (D2O). 
1H NMR δH (300 MHz, D2O): 4.41 (1H, m), 3.74(44xH + 4H m), 
3.07 (2H, m), 1.82 (4H, m). x: percentage of modification. 
1.2. NMR 
1H-NMR Experiments 
NMR spectra were recorded at 27 °C (300 K) on an Avance III 
500 MHz Bruker spectrometer equipped with a 5 mm TBI 
broadband probe or a 300 Ultrashield from Bruker (Billerica, 
MA, USA). Data were processed with the software Mestrenova 
(Bruker GmbH, Karlsruhe, Germany). Samples were prepared at 
the desired concentration in D2O. 
Diffusion Experiments  
Pulsed-field gradient NMR spectroscopy was employed to 
measure translational diffusion by fitting the integrals or 
intensities of the NMR signals to the Stejskal−Tanner equation 
[38, 39]: I= I0 exp[-Dγ2g2δ2(Δ-δ ⁄ 3)] where I is the observed 
intensity, I0 the reference intensity (unattenuated signal 
intensity), D the diffusion coefficient, γ the gyromagnetic ratio 
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of the observed nucleus, g the gradient strength, δ the length of 
the gradient, and Δ the diffusion time. Two-dimensional 
diffusion-ordered NMR spectroscopy (DOSY) was performed 
with a stimulated echo sequence using bipolar gradient pulses. 
The lengths of delay were held constant at Δ= 100 ms, and 32 
spectra of 64 scans, 10 each were acquired with the strength of 
the diffusion gradient varying between 5% and 95%. The lengths 
of the diffusion gradient and the stimulated echo were 
optimized for each sample.  
1.3 Gel Permeation Chromatography 
Gel Permeation Chromatography (GPC) was performed in an 
AF2000 system from Postnova Analytics (Landsberg, Germany) 
using aqueous media containing 0.1 M of NaNO3 and 0.005% 
(w/w) sodium azide as an additive. The system was configured 
to work on GPC mode with an isocratic pump (PN1130) an 
autosampler (PN5300), a 6 refractive index (RI, PN3150), 21 
angle-multi angle light scattering (MALS, PN3621) and an 
ultraviolet-visible (UV-VIS) (PN3211) detectors. A working flow 
rate of 0.7 mL/min for 40 min at 30°C was employed with one 
TSKgel G50000PWxl-CP column. 40 μL of a polymer solution of 
5 mg/mL was injected each time. 
1.4 PLO Degradation Studies 
A cocktail of bacterial proteases from Streptomyces griseus was 
used as a degradation matrix. A compound analogous to P2, but 
synthesized with PLO150 instead PLO50, was used to explore 
the stability of the PLO polymer. This derivative was spiked into 
the protease cocktail matrix at a final polymer concentration of 
10 mg/mL, with the matrix diluted to a protein concentration of 
10 mg/mL and buffered to pH 6.0 with 20mM Tris. The mixture 
was incubated at 37°C under agitation (300 rpm), and 120 μL 
aliquots were removed at each desired time point and analyzed 
by GPC under the same conditions detailed in section 1.3.  
2. Preparation and Characterization of siRNA polyplexes 
2.1 Polyplex formation - N/P ratio Optimization 
500 ng of dsDNA/siRNA and the calculated amount of polymer 
at indicated charge-ratio (+/-) or amine to phosphate ratio (N/P) 
were diluted in separate tubes in 20 mM HEPES buffer at pH 7.4 
each. Only protonable nitrogens, not amide nitrogens, were 
considered in the +/- ratio and N/P ratio calculations. The 
nucleic acid and the polymer solution were mixed by rapidly 
pipetting up and down (at least five times) and incubating for 
20 min at RT before next usage. 
Electrophoresis assays were carried out to ensure polyplex 
formation. A 2.5 wt% agarose gel was prepared by dissolving 
agarose in TAE buffer (Tris base, acetic acid, and EDTA) and 
boiling at 100 °C. After cooling to 50 °C and GelRed addition, the 
agarose gel was set in an electrophoresis unit. Polyplexes 
containing 500 ng of siRNA/dsDNA in 20 μL HEPES 20mM and 
loading buffer were placed into the sample lanes. 
Electrophoresis was performed at 80 V for 80 min.  
2.2 Size and Zeta-potential Determination 
DLS measurements were performed using a Malvern ZetaSizer 
NanoZS instrument, equipped with a 532 nm laser at a fixed 
scattering angle of 173° (Malvern Instruments, Worcestershire, 
UK). Polyplex solutions were filtered through a 0.45 μm 
cellulose membrane filter and measured in a DTS 1070 cell. Size 
distribution was measured (diameter, nm) for each compound 
in triplicate preparations, each with n > 3 measurements. For 
size measurements, polyplex solutions were prepared in HEPES 
20mM pH=7.4 at 0.012-0.014 mg/mL and measured at 25 °C. 
Automatic optimization of beam focusing and attenuation was 
applied for each sample. Zeta-potential measurements were 
performed using disposable folded capillary cells, provided by 
Malvern Instruments Ltd. Polymer solutions were prepared 
under the same conditions as for size measurements. The zeta 
(ζ)-potential was calculated using the Smoluchowski model. 
Accordingly, 10–30 sub-runs of 10 s at 25 °C (n = 3) were 
measured. 
TEM images were recorded using a JEOL 2100 transmission 
electron microscope. Samples of polyplexes were applied 
directly onto carbon film on 200 mesh copper grids. Excess of 
the sample was carefully removed by capillarity, and the grids 
were immediately stained with one drop of 2% uranyl acetate 
for 30 s. Excess of staining was likewise removed by capillarity. 
2.3 Gel Electrophoresis Studies of Polymer Stability 
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Heparin Displacement Assay 
The strength of the dsDNA/siRNA-polymer interaction was 
examined by heparin competitive displacement assay [40]. 
Polyplexes were incubated with heparin (0.75 IU /mL; 50 IU/mL 
and 250 IU/mL) and evaluated by gel electrophoresis/UV 
illumination as described in Section 2.1 to observe 
dsDNA/siRNA release.  
Plasma Stability by Gel Shift Assay 
Polyplexes prepared as in section 2.1 were incubated in a 
solution containing 20% mouse serum at 37 ˚C and different 
incubation times (0 h, 2 h, 3 h, and 5 h) to determine plasma 
stability. Subsequently, an agarose gel electrophoresis assay 
was performed using the same protocol described above.  
Cell Culture Media Stability by Gel Shift Assay 
Polyplexes were incubated in a solution containing 80% cell 
culture media (B16-F10 or OPC media) at 37 ˚C and different 
incubation times (0, 1, 5, and 24 h) to ensure cell culture media 
stability.  Subsequently, an agarose gel electrophoresis assay 
was performed using the same protocol described above. 
Storage Stability by Gel Shift Assay 
Polyplexes prepared as in section 2.1 were stored at 4˚C for 15 
days to study polyplex stability during storage. Subsequently, an 
agarose gel electrophoresis assay was performed using the 
same protocol described above.  
2.4 Circular Dichroism 
Circular dichroism (CD) spectroscopy was performed with a J-
815 CD Spectrometer (JASCO Corporation) using a Peltier 
thermostated cell holder (PTC-423, JASCO 15 Corporation) with 
a recirculating cooler (JULABO F250, JASCO Corporation). A 
nitrogen flow (~2.7 L/min) was filtered through the 
spectrometer and controlled with a nitrogen flow monitor 
(Afriso Euro-Index). The samples (polymer, polyplex, and 
dsDNA) were dissolved in phosphate buffer (PB) pH 7.4, at 0.15 
mg/mL. Samples were measured repeatedly (n= 3) in a quartz 
cuvette with d = 0.1 cm at 20°C. Obtained molar ellipticities 
were plotted as mean residue ellipticity. 
2.5 Polyplex Haemocompatibility Evaluation  
Red blood cells (RBC) were isolated from fresh mouse blood 
obtained by cardiac puncture after death and placed in a tube 
with an anticoagulant compound (0.5M EDTA, 1/10 volume) on 
ice. Blood was diluted with PBS pH 7.4 up to 10 mL and then 
centrifuged (3000 rpm, 10 min, 4°C, x 3), removing the 
supernatant after each centrifugation and re-suspending the 
cells in sterile PBS. The final RBC pellet was weighed and 
resuspended at 2% (v/v) in sterile PBS. Stock solutions were 
dissolved in PBS adjusted to pH 6.5 or 7.4 and citrate solution 
adjusted to pH 5.5 to mimic different stages in the endo-
lysosomal pathway to study the hemolytic activity of the 
polymers and the polyplexes. Samples were added to wells 
(n=3, 100 μL) covering the concentration range 0.1-0.005 
mg/mL of systems (0.1, 0.05, 0.01, and 0.005 mg/mL). Buffer at 
the corresponding pH was used as a control. Triton X–100 1% 
(w/v) was used as a positive control to determine a 100% RBC 
lysis and dextran (2 mg/mL) was used as a negative control. The 
plates were then incubated at 37 °C for 1 h. Plates were 
centrifuged (3000 rpm, 10 min, 20°C) and the supernatant of 
each well was transferred into a new plate to assess hemoglobin 
(Hb) release. The hemoglobin released was assessed by 
measuring the absorbance at 570 nm using a Wallac Victor2 
plate reader. The percentage of hemolysis of each sample was 
calculated relative to 100% hemolysis obtained from incubation 
with Triton-X 100. 
3. Cell Culture Studies 
3.1 Cell-Culture 
Murine melanoma cells B16-F10-luc-G5 (B16-F10) cells which 
stably express firefly luciferase were cultured at 37 °C in a 5% 
CO2 atmosphere using DMEM medium supplemented with 10% 
FBS, 2 mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL 
streptomycin. Cells were maintained at 37 °C in an atmosphere 
of 5% CO2 and 95% air, and they underwent passage twice 
weekly when 80% cell confluence was reached. 
Primary OPCs were isolated using A2B5-primary antibody 
(Millipore) and anti-IgM Microbeads for positive magnetic cell 
sorting following Miltenyi Biotech indications with some 
modifications, as previously described [41] (Supporting 
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Information). Briefly, P4-P7 rats were euthanized via an 
intraperitoneal injection of Pentoject and then decapitated 
following schedule 1 procedures (Animal Scientific Procedure 
Act 1986). The brains were cut into small pieces and digested 
with a papain solution containing 1:25 papain and 1:100 DNase 
in HALF (“Hibernate A low fluorescence” made in-house) for 30 
min at 35 °C. Following tissue digestion, papain was removed 
with HBSS (-/-) (without Ca2+ and Mg2+) washes and via 
centrifugation. The tissue was then triturated with HALF with 1X 
B27 and 2 mM sodium pyruvate first, and the single-cell 
suspension was passed through a 70 µm strainer. The remaining 
tissue bits were triturated a second and third time with HALF 
with 0.1% pluronic acid and 2 mM sodium pyruvate and the 
single-cell suspension transferred through a 70µm strainer. The 
single-cell suspension was centrifuged for 20 min at 800 x g in a 
22.5% Percoll (GE Healthcare) solution with DMEM F12. 
Following centrifugation, Percoll was removed by aspiration, 
and the cells were washed with HBSS (-/-). Cells were incubated 
with A2B5 antibody (MAB312) for 25 min at 4 °C in wash buffer 
(0.5% BSA, 2 mM sodium pyruvate, 2 mM EDTA and 10 ug/ml 
insulin in 1X PBS). Excess of antibody was washed away with 
HBSS (-/-), and cells were incubated with secondary IgM-
microbeads for 15 min at 4 °C in wash buffer. Excess of antibody 
was again removed by washing with HBSS (-/-), and the cells 
were magnetically sorted following the manufacturer’s 
instructions (Miltenyi Biotech). Cells were eluted in OPC media 
with 20ng/mL of bFGF and 20ng/mL PDGF-AA and plated in 
poly-D-lysine coated coverslips. The OPCs cells were kept under 
in culture and media with growth factors (20 ng/mL bFGF and 
20 ng/mL PDGF-AA) was added every other day. 
3.2 Cell cytotoxicity Studies 
MTS Assay for Cell Viability Evaluation  
B16-F10 cells were seeded into sterile 96-well plates at a density 
of 10,000 cells per well. After 24 h, the culture medium was 
replaced with 80 µL of fresh growth medium containing 10% 
FBS. Then, 20 µL of parent polymers or polyplexes solution (0.2 
µm filter sterilized) at different +/- or N/P ratios were added. 
Studies were performed in triplicate (n=8 samples). 48 h post-
transfection, 10 µL of a solution containing MTS/phenazine 
methosulfate (PMS) (20:1) were added to each well, and the 
cells were incubated for a further 2 h. The optical density of 
each well was measured spectrophotometrically at 490 nm 
using a Wallac Victor2 plate reader. The absorbance values 
were represented as the percentage of cell viability relative to 
the viability of untreated control cells (100%).  
LDH assay for cell viability 
The toxicity of polyplexes in primary OPCs was ascertained using 
an LDH-Cytotoxicity II kit following the instructions provided by 
the supplier. Toxicity/viability was normalized to non-treated 
cells (100% viability) and samples lysed with a 10% solution of 
Triton X-100 (0% viability). Assays were performed on the 
supernatant of treated/non-treated OPCs at 48 h post-
transfection. This time point included a medium change at 6 h 
post-transfection. 
4. In vitro transfection 
4.1 Luciferase Silencing 
B16-F10 cells were seeded in sterile 96-well plates in 100 μL 
medium (10,000 cells per well). After 24 h, the medium was 
exchanged for 80 μL fresh medium. The formed polyplexes 
containing 500 ng of siRNA (scrambled siRNA or luciferase 
silencing siRNA) per well were added in a volume of 20 μL to 
each well and incubated at 37 °C. Lipofectamine RNAiMAX at 
non-toxic optimum N/P ratio with scrambled siRNA or luciferase 
silencing siRNA were used as positive controls for transfection 
efficiency, according to manufacturer instructions. All 
experiments were performed in triplicate. 48 h after 
transfection, cells were treated with 20 μL of Bright-Glo reagent 
(luciferin (150 μg/mL) in PBS). Luciferase activity was 
spectrophotometrically quantified using a Wallac Victor2 plate 
reader (λem 535 nm). 
4.2 DR6 silencing in OPCs 
24 h prior to transfection, penicillin, and streptomycin were 
removed from the cell media to avoid interference with the 
Lipofectamine transfection. Polyplexes, parent polymers or 
Lipofectamine RNAiMAX complexes were incubated for 6h at 
cell culture conditions. Then, the medium was removed, and 
new cell media with growth factors (bFGF and PDGF-AA) was 
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added. RNA was collected 48h after transfection, and protein 
collection was performed 4 days after transfection. 
  4.2.1 Gene expression Through Real-Time qPCR 
Primary OPCs were seeded in sterile 12-well plates (previously 
coated with PDL 5 µg/mL) at 80,000 cell/well. Every other day 
the medium was exchanged for fresh medium. Compounds 
(polyplexes with scrambled siRNA or DR6-silencing siRNA, 
parent polymers, and Lipofectamine RNAiMAX with scramble 
siRNA or DR6-silencing siRNA) were incubated for 6 h at 37 °C 
and then replaced by fresh media. 48h post-transfection, total 
RNA was extracted using QIAzol Lysis reagent and the protocol 
provided by the supplier. RNA was quantified using a NanoDrop 
2000 spectrophotometer with purity assessed by means of 
A260/A280 and A260/A230 ratios. From 500 ng of total RNA, 
cDNA was generated using a High-Capacity cDNA Reverse 
Transcription kit using random hexamer primers. qRT-PCR was 
subsequently performed using TaqMan reagents (TaqMan Fast 
Universal PCR Master Mix [2x] and FAM-labeled TaqMan Gene 
Expression Assays) and an Applied Biosystems 7500 Fast real-
time PCR system. Mouse Gapdh (VIC labeled) was used as a 
reference gene for determining relative Tnfrsf21 gene 
expression using the 2-ΔΔCt method [42]. Each biological sample 
was measured in triplicate, and the experiment was performed 
with three independent biological replicates. 
  4.2.2 Protein Expression Analysis  
Primary OPCs were seeded in sterile 6-well plates (previously 
coated with PDL as previously indicated) at 200,000 cells/well. 
Every other day, fresh medium was added to the cells. 
Compounds (polyplexes with scramble siRNA or DR6-silencing 
siRNA, parent polymers, and Lipofectamine with scramble 
siRNA or DR6-silencing siRNA) were incubated for 6 h at 37°C 
and then replaced with fresh media. Cells were collected 4 days 
post-transfection. Proteins were extracted by solubilization in 
RIPA buffer with the addition of Complete Protease Inhibitor 
Cocktail and Halt Phosphatase Inhibitor Cocktail, and 1 mM 
PMSF to inhibit serine proteases. Cell lysates were centrifuged 
at 10,000 rpm for 10 min at 4°C. Supernatants were collected, 
and protein concentration was determined using Bio-Rad 
Protein Assay. Sample volumes equivalent to 15 µg of total 
protein were mixed with 5 × SDS sample buffer, boiled for 5 min 
and separated through 12.5% SDS-PAGE gels. After 
electrophoresis, the proteins were transferred to nitrocellulose 
membranes by electrophoretic transfer. The transfer was 
confirmed by Ponceau S staining. The membranes were blocked 
in 5% skimmed milk for 1 h, rinsed, and incubated overnight at 
4°C with the primary antibodies: DR6/TNFRSF21 (1:500 
dilution), cleaved Caspase-3 (1:5000 dilution), PARP (1:500) and 
β-actin (1:1000). Excess antibody was then removed by washing 
the membrane in PBS/0.1% Tween 20, and the membranes 
were incubated for 1 h with horseradish peroxidase-conjugated 
secondary antibodies: mouse anti-rabbit IgG (1:5000), goat anti-
rabbit IgG (1:4000), mouse anti-rabbit IgG (1:5000) and anti-
mouse IgG (1:10000) (respectively). After washing with 
PBS/0.1% Tween 20, immuno-detection was performed using 
the ECL Prime Western Blotting Detection system, according to 
the manufacturer's instructions. Densitometry measurements 
were performed using Fiji, with each protein band being 
normalized to the β-actin loading controls. 
  4.2.3 Immunofluorescent Studies  
OPCs were seeded on a 9 mm glass coverslip (VWR) at a density 
of 2000 cells/coverslip with daily supplementation 10 ng/mL of 
PDGF-AA and 10 ng/mL of bFGF. After three days, the coverslips 
were transferred to 48 well-plates and siRNA experiments 
performed as described above. Cells were fixed after 48h of 
incubation with 4% PFA for 15 min and then washed twice with 
PBS prior to proceeding to immunocytochemistry. 
Cells were blocked with 5% normal donkey serum (NDS) with 
0.01% triton for 1 h at RT. Cells were then incubated with 
primary antibodies diluted in blocking solution for 1h at RT: 
rabbit Olig2 (1:500), mouse CNP (1:500). Excess primary 
antibody was washed away with PBS, and cells were incubated 
with secondary antibodies in blocking solution for 1 h at RT. 
Upon secondary antibody incubation, the excess of antibody 
was washed out, and cells were incubated again with primary 
antibody against O4 (1:500) for 1h at RT in blocking solutions. 
Again, the excess of antibody was washed out with PBS, and the 
cells were incubated with the corresponding secondary for 1h 
at RT. After washing away the excess of the secondary antibody, 
the cells were stained with Hoechst (1:5000) and coverslips 
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were mounted with Fluoromount G. Images were taken using a 
Leica SP5 confocal. 
5. Statistical Analyses 
Data from the experiments were analyzed using one-way 
ANOVA and Bonferroni posthoc for pairwise comparison. In all 
cases, differences were considered to be significant when ***p 
< 0.001; **p < 0.01; *p < 0.05; ns: nonsignificant. 
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